385 related articles for article (PubMed ID: 29467311)
21. B Cell-Specific Transcription Activator PAX5 Recruits p300 To Support EBNA1-Driven Transcription.
Liu CD; Lee HL; Peng CW
J Virol; 2020 Mar; 94(7):. PubMed ID: 31941781
[TBL] [Abstract][Full Text] [Related]
22. Epstein-Barr virus nuclear antigen 2 transactivates the long terminal repeat of human immunodeficiency virus type 1.
Scala G; Quinto I; Ruocco MR; Mallardo M; Ambrosino C; Squitieri B; Tassone P; Venuta S
J Virol; 1993 May; 67(5):2853-61. PubMed ID: 8386279
[TBL] [Abstract][Full Text] [Related]
23. Epstein-barr virus nuclear antigen 3C activates the latent membrane protein 1 promoter in the presence of Epstein-Barr virus nuclear antigen 2 through sequences encompassing an spi-1/Spi-B binding site.
Zhao B; Sample CE
J Virol; 2000 Jun; 74(11):5151-60. PubMed ID: 10799590
[TBL] [Abstract][Full Text] [Related]
24. Epstein-Barr Virus B Cell Growth Transformation: The Nuclear Events.
Zhao B
Viruses; 2023 Mar; 15(4):. PubMed ID: 37112815
[TBL] [Abstract][Full Text] [Related]
25. The NP9 protein encoded by the human endogenous retrovirus HERV-K(HML-2) negatively regulates gene activation of the Epstein-Barr virus nuclear antigen 2 (EBNA2).
Gross H; Barth S; Pfuhl T; Willnecker V; Spurk A; Gurtsevitch V; Sauter M; Hu B; Noessner E; Mueller-Lantzsch N; Kremmer E; Grässer FA
Int J Cancer; 2011 Sep; 129(5):1105-15. PubMed ID: 21710493
[TBL] [Abstract][Full Text] [Related]
26. Determining the role of the Epstein-Barr virus Cp EBNA2-dependent enhancer during the establishment of latency by using mutant and wild-type viruses recovered from cottontop marmoset lymphoblastoid cell lines.
Yoo L; Speck SH
J Virol; 2000 Dec; 74(23):11115-20. PubMed ID: 11070007
[TBL] [Abstract][Full Text] [Related]
27. The Epstein-Barr Virus Enhancer Interaction Landscapes in Virus-Associated Cancer Cell Lines.
Ding W; Wang C; Narita Y; Wang H; Leong MML; Huang A; Liao Y; Liu X; Okuno Y; Kimura H; Gewurz B; Teng M; Jin S; Sato Y; Zhao B
J Virol; 2022 Sep; 96(18):e0073922. PubMed ID: 36094314
[TBL] [Abstract][Full Text] [Related]
28. A single amino acid in EBNA-2 determines superior B lymphoblastoid cell line growth maintenance by Epstein-Barr virus type 1 EBNA-2.
Tzellos S; Correia PB; Karstegl CE; Cancian L; Cano-Flanagan J; McClellan MJ; West MJ; Farrell PJ
J Virol; 2014 Aug; 88(16):8743-53. PubMed ID: 24850736
[TBL] [Abstract][Full Text] [Related]
29. Epstein-Barr virus nuclear antigen EBNA-LP is essential for transforming naïve B cells, and facilitates recruitment of transcription factors to the viral genome.
Szymula A; Palermo RD; Bayoumy A; Groves IJ; Ba Abdullah M; Holder B; White RE
PLoS Pathog; 2018 Feb; 14(2):e1006890. PubMed ID: 29462212
[TBL] [Abstract][Full Text] [Related]
30. The BHLF1 Locus of Epstein-Barr Virus Contributes to Viral Latency and B-Cell Immortalization.
Yetming KD; Lupey-Green LN; Biryukov S; Hughes DJ; Marendy EM; Miranda JL; Sample JT
J Virol; 2020 Aug; 94(17):. PubMed ID: 32581094
[TBL] [Abstract][Full Text] [Related]
31. EBNA2-EBF1 complexes promote MYC expression and metabolic processes driving S-phase progression of Epstein-Barr virus-infected B cells.
Beer S; Wange LE; Zhang X; Kuklik-Roos C; Enard W; Hammerschmidt W; Scialdone A; Kempkes B
Proc Natl Acad Sci U S A; 2022 Jul; 119(30):e2200512119. PubMed ID: 35857872
[TBL] [Abstract][Full Text] [Related]
32. TAF Family Proteins and MEF2C Are Essential for Epstein-Barr Virus Super-Enhancer Activity.
Wang C; Jiang S; Zhang L; Li D; Liang J; Narita Y; Hou I; Zhong Q; Gewurz BE; Teng M; Zhao B
J Virol; 2019 Aug; 93(16):. PubMed ID: 31167905
[TBL] [Abstract][Full Text] [Related]
33. Counteracting effects of cellular Notch and Epstein-Barr virus EBNA2: implications for stromal effects on virus-host interactions.
Rowe M; Raithatha S; Shannon-Lowe C
J Virol; 2014 Oct; 88(20):12065-76. PubMed ID: 25122803
[TBL] [Abstract][Full Text] [Related]
34. The Epstein-Barr virus BamHI C promoter is not essential for B cell immortalization in vitro, but it greatly enhances B cell growth transformation.
Tierney RJ; Nagra J; Rowe M; Bell AI; Rickinson AB
J Virol; 2015 Mar; 89(5):2483-93. PubMed ID: 25540367
[TBL] [Abstract][Full Text] [Related]
35. EBNA2 driven enhancer switching at the CIITA-DEXI locus suppresses HLA class II gene expression during EBV infection of B-lymphocytes.
Su C; Lu F; Soldan SS; Lamontagne RJ; Tang HY; Napoletani G; Farrell PJ; Tempera I; Kossenkov AV; Lieberman PM
PLoS Pathog; 2021 Aug; 17(8):e1009834. PubMed ID: 34352044
[TBL] [Abstract][Full Text] [Related]
36. Protein kinase A associates with HA95 and affects transcriptional coactivation by Epstein-Barr virus nuclear proteins.
Han I; Xue Y; Harada S; Orstavik S; Skalhegg B; Kieff E
Mol Cell Biol; 2002 Apr; 22(7):2136-46. PubMed ID: 11884601
[TBL] [Abstract][Full Text] [Related]
37. Variable methylation of the Epstein-Barr virus Wp EBNA gene promoter in B-lymphoblastoid cell lines.
Elliott J; Goodhew EB; Krug LT; Shakhnovsky N; Yoo L; Speck SH
J Virol; 2004 Dec; 78(24):14062-5. PubMed ID: 15564516
[TBL] [Abstract][Full Text] [Related]
38. Transcription of the Epstein-Barr virus nuclear antigen 1 (EBNA1) gene occurs before induction of the BCR2 (Cp) EBNA gene promoter during the initial stages of infection in B cells.
Schlager S; Speck SH; Woisetschläger M
J Virol; 1996 Jun; 70(6):3561-70. PubMed ID: 8648690
[TBL] [Abstract][Full Text] [Related]
39. Modulation of enhancer looping and differential gene targeting by Epstein-Barr virus transcription factors directs cellular reprogramming.
McClellan MJ; Wood CD; Ojeniyi O; Cooper TJ; Kanhere A; Arvey A; Webb HM; Palermo RD; Harth-Hertle ML; Kempkes B; Jenner RG; West MJ
PLoS Pathog; 2013 Sep; 9(9):e1003636. PubMed ID: 24068937
[TBL] [Abstract][Full Text] [Related]
40. Identification of Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA2) target proteins by proteome analysis: activation of EBNA2 in conditionally immortalized B cells reflects early events after infection of primary B cells by EBV.
Schlee M; Krug T; Gires O; Zeidler R; Hammerschmidt W; Mailhammer R; Laux G; Sauer G; Lovric J; Bornkamm GW
J Virol; 2004 Apr; 78(8):3941-52. PubMed ID: 15047810
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
